ZNTL Insider Trading Activity and SEC Form 4 Filings
ZNTL insider trading summary
Over the past 12 months, insiders at Zentalis Pharmaceuticals, Inc. (ZNTL) reported 11 sales worth $20.1M by 5 insiders and 6 open-market purchases worth $68.8M by 3 insiders on SEC Form 4. Net insider buying was $48.7M.
Latest ZNTL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 14, 2026 | William Thurman Walters | 10% Owner | Buy | $15.2M (4,335,000 @ $3.50) |
| Aug 14, 2026 | Susan Berkley Walters | 10% Owner | Buy | $15.2M (4,335,000 @ $3.50) |
| Aug 14, 2026 | Walters Group | 10% Owner | Buy | $15.2M (4,335,000 @ $3.50) |
| Feb 10, 2026 | Vincent Vultaggio | PAO and PFO | Sell | $17K (6,894 @ $2.42) |
| Feb 9, 2026 | Julia Marie Eastland | CEO & President | Sell | $2K (889 @ $2.39) |
| Feb 9, 2026 | Vincent Vultaggio | PAO and PFO | Sell | $8K (3,379 @ $2.39) |
| Feb 9, 2026 | Ingmar Bruns | Chief Medical Officer | Sell | $802 (335 @ $2.39) |
| Feb 6, 2026 | Julia Marie Eastland | CEO & President | Sell | $19K (7,866 @ $2.43) |
| Feb 6, 2026 | Ingmar Bruns | Chief Medical Officer | Sell | $7K (2,962 @ $2.43) |
| Feb 6, 2026 | Vincent Vultaggio | PAO and PFO | Sell | $73K (29,951 @ $2.43) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.